^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Free radical stimulant

    Related drugs:
    2d
    Elucidation of a Novel Protective Function of AADAC Against Drug-induced Liver Injury through Ferroptosis Suppression (PubMed, Yakugaku Zasshi)
    Using Aadac knockout (KO) mice, we demonstrated that CCl4, APAP, and amodiaquine induced more severe liver damage in the absence of Aadac, with elevated ferrous (Fe2+) levels, lipid peroxidation, and oxidative stress...Furthermore, human AADAC overexpression in Huh-7 cells similarly reduced intracellular Fe2+ levels and conferred protection against CCl4-induced cytotoxicity in a ceruloplasmin-dependent manner. These findings reveal a novel, non-catalytic role for AADAC in iron homeostasis and ferroptosis suppression, suggesting its clinical significance in DILI susceptibility and therapy.
    Review • Journal
    |
    AADAC (Arylacetamide Deacetylase)
    11d
    NBTXR3, Radiation Therapy, and Pembrolizumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Cancer (clinicaltrials.gov)
    P2, N=14, Terminated, M.D. Anderson Cancer Center | Trial completion date: Sep 2026 --> Jan 2026 | Active, not recruiting --> Terminated | Trial primary completion date: Sep 2026 --> Jan 2026; <75% participation
    Trial completion date • Trial termination • Trial primary completion date • IO biomarker
    |
    PD-L1 (Programmed death ligand 1)
    |
    Keytruda (pembrolizumab) • Hensify (crystalline hafnium oxide)
    22d
    ALAQ: Pharmacokinetic Study of Artemether-lumefantrine and Amodiaquine in Healthy Subjects (clinicaltrials.gov)
    P1, N=8, Terminated, University of Oxford | N=16 --> 8 | Trial completion date: Aug 2026 --> Apr 2025 | Recruiting --> Terminated | Trial primary completion date: Aug 2026 --> Apr 2025; The decision was made due to the expired investigational drug and regulatory changes by the Thai FDA, along with increased importation costs. The research team and investigational drug sponsor agreed to seek approval for early project termination.
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    27d
    PMC-VAC: Perennial Malaria Chemoprevention in the Malaria Vaccine Era (clinicaltrials.gov)
    P4, N=1290, Not yet recruiting, Stanford University
    New P4 trial
    2ms
    LUMIRAY: A Study of JNJ-90301900 in Combination With Chemoradiation Therapy in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov)
    P1, N=30, Recruiting, Johnson & Johnson Enterprise Innovation Inc. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Hensify (crystalline hafnium oxide)
    2ms
    NANORAY-312: JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC (clinicaltrials.gov)
    P3, N=500, Recruiting, Johnson & Johnson Enterprise Innovation Inc. | Trial completion date: Dec 2027 --> Jun 2028
    Trial completion date
    |
    Erbitux (cetuximab) • Hensify (crystalline hafnium oxide)
    2ms
    Efficacy and safety of artesunate-amodiaquine for the treatment of uncomplicated Plasmodium falciparum in Eritrea in 2022 (ACTRN12625001329459)
    P4, N=352, Completed, Ministry of Health
    New P4 trial
    3ms
    SAFIRE: Safety of Antimalarials in the FIRst trimEster (clinicaltrials.gov)
    P3, N=1510, Recruiting, Liverpool School of Tropical Medicine | Not yet recruiting --> Recruiting | Initiation date: Jul 2025 --> Sep 2025
    Enrollment open • Trial initiation date • Head-to-Head
    3ms
    FD-TACT: A Study to Find Out if a Combination of 3 Medicines for the Treatment of Malaria Works as Well and is as Safe and Tolerable as Combinations of 2 Medicines (clinicaltrials.gov)
    P3, N=1680, Recruiting, University of Oxford | Not yet recruiting --> Recruiting | Trial completion date: May 2025 --> Jul 2026 | Trial primary completion date: Nov 2024 --> Jul 2026
    Enrollment open • Trial completion date • Trial primary completion date • Head-to-Head
    3ms
    DeTACT-Africa: A Trial to Compare the Efficacy, Safety and Tolerability of Combinations of 3 Anti-malarial Drugs Against Combina-tions of 2 Anti-malarial Drugs. (clinicaltrials.gov)
    P3, N=2583, Completed, University of Oxford | Recruiting --> Completed
    Trial completion • Head-to-Head
    3ms
    NBTXR3 and Radiation Therapy for the Treatment of Inoperable Recurrent Non-small Cell Lung Cancer (clinicaltrials.gov)
    P1, N=34, Active, not recruiting, M.D. Anderson Cancer Center | Recruiting --> Active, not recruiting | N=24 --> 34
    Enrollment closed • Enrollment change
    |
    Hensify (crystalline hafnium oxide)
    3ms
    NBTXR3 With Radiation Therapy Alone for Locally-advanced Non-small Cell Lung Cancer (clinicaltrials.gov)
    P1/2, N=40, Not yet recruiting, M.D. Anderson Cancer Center
    New P1/2 trial
    |
    Hensify (crystalline hafnium oxide)